Trial of Rosiglitazone in Liposarcoma Patients
Author Information
Author(s): Guy Debrock, Vanhentenrijk V, Sciot R, Debiec-Rychter M, Oyen R, Van Oosterom A
Primary Institution: University Hospital Gasthuisberg, Universiteit Leuven
Hypothesis
Can rosiglitazone induce differentiation in liposarcoma patients?
Conclusion
The study found that while there was some biological activity of rosiglitazone, it did not lead to significant clinical improvement in liposarcoma patients.
Supporting Evidence
- The mean progression-free survival period was 5.5 months.
- No significant morphological signs of redifferentiation were detected.
- Only two patients showed a limited upregulation of gene expression linked to adipocytic differentiation.
Takeaway
Doctors tried a medicine called rosiglitazone to help patients with a type of cancer called liposarcoma, but it didn't really work as they hoped.
Methodology
Nine liposarcoma patients were treated with rosiglitazone, and their clinical, histological, and biological parameters were documented.
Potential Biases
Potential sampling errors due to the heterogeneous nature of liposarcomas.
Limitations
The study had a small sample size and some patients were not evaluable due to rapid disease progression.
Participant Demographics
Patients had a mean age of 58 years at the start of treatment, with various subtypes of liposarcoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website